Press Enter to search · ESC to close

Macro

BioNTech Buys FDA Priority Review Voucher for $205M

BioNTech has purchased an FDA priority review voucher for $205 million. The voucher allows its holder to expedite regulatory review of a single drug application. The transaction was reported by Bloomberg, which did not specify which product the company intends to use the voucher for.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback